financetom
Business
financetom
/
Business
/
ITT Q3 profit beats estimates on strong aerospace and defense demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ITT Q3 profit beats estimates on strong aerospace and defense demand
Oct 29, 2025 3:59 AM

Overview

* ITT Q3 revenue rose 13% yr/yr to $999 mln, driven by aerospace and defense

* Adjusted EPS for Q3 was $1.78, beating analyst expectations

* Company raised full-year revenue, EPS, and cash flow guidance

Outlook

* ITT raises 2025 revenue growth forecast to 6%-7%

* Company expects 2025 EPS of $6.16-$6.22, adj EPS $6.62-$6.68

* ITT projects 2025 free cash flow of $500 mln

Result Drivers

* AEROSPACE AND DEFENSE - Revenue growth driven by strength in aerospace and defense sectors

* PUMP PROJECTS - Strength in pump projects contributed significantly to revenue growth

* PRODUCTIVITY AND PRICING - Adjusted operating income increased due to productivity savings and pricing actions

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $999.10

Revenue mln

Q3 Beat $1.78 $1.66

Adjusted (11

EPS Analysts

)

Q3 EPS $1.62

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the industrial machinery & equipment peer group is "buy"

* Wall Street's median 12-month price target for ITT Inc ( ITT ) is $200.00, about 12.1% above its October 28 closing price of $175.89

* The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRT Apartments Acquires Apartment Complex in Georgia
BRT Apartments Acquires Apartment Complex in Georgia
Oct 6, 2025
08:08 AM EDT, 10/06/2025 (MT Newswires) -- BRT Apartments ( BRT ) said Monday that it acquired Oaks at Victory, a 150-unit apartment complex in Savannah, Georgia. The company said it acquired the property for $23 million through a joint venture in which it owns an 80% equity interest. BRT said it borrowed $8 million from its credit facility to...
Talen Energy Unit Launches $1.2 Billion Term Loan for Power Plant Acquisitions
Talen Energy Unit Launches $1.2 Billion Term Loan for Power Plant Acquisitions
Oct 6, 2025
08:06 AM EDT, 10/06/2025 (MT Newswires) -- Talen Energy ( TLN ) said Monday that its Talen Energy Supply subsidiary launched a $1.2 billion incremental term loan B financing. The company also said it received commitments to upsize its existing $700 million revolving credit facility to $900 million and its existing $900 million stand-alone letter of credit facility to $1.1...
Gogo Gets FAA Approval for Galileo FDX on Boeing Business Jet 737-Series Aircraft
Gogo Gets FAA Approval for Galileo FDX on Boeing Business Jet 737-Series Aircraft
Oct 6, 2025
08:08 AM EDT, 10/06/2025 (MT Newswires) -- Gogo ( GOGO ) said Monday its Galileo FDX terminal received Federal Aviation Administration's supplemental type certificate approval for installation on Boeing Business Jets 737-series aircraft. The approval covers Boeing 737NG-based BBJ1, BBJ2 and BBJ MAX aircraft, and can be modified for other BBJ 737 STC variants, the company said. Gogo ( GOGO...
Stoke Therapeutics Names Ian Smith CEO
Stoke Therapeutics Names Ian Smith CEO
Oct 6, 2025
08:07 AM EDT, 10/06/2025 (MT Newswires) -- Stoke Therapeutics ( STOK ) said Monday it has named Ian Smith its chief executive officer. Smith, who has has been Stoke Therapeutics' ( STOK ) interim CEO since March, will remain a board member, the company said. Stoke Therapeutics ( STOK ) also said that Arthur Tzianabos will return to his position...
Copyright 2023-2026 - www.financetom.com All Rights Reserved